Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors-Reference-Cited by-同舟云学术

Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors

Published:2023-02-03 Issue: Volume: Page:
ISSN:0882-8245
Container-title:Viral Immunology
language:en
Short-container-title:Viral Immunology

Author:

Lobaina Yadira¹²,Chen Rong¹³,Ai Panchao¹³,Yang Liling⁴,Alvarez-Lajonchere Liz²,Suzarte Edith²,Tan Changyuan¹³,Silva Ricardo¹⁵,Jiang Zaixue⁶,Yang Ke¹³,Perera Yasser¹²,Hermida Lisset¹⁵^ORCID

Affiliation:

1. CCBJIC: China-Cuba Biotechnology Joint Innovation Center, Yongzhou, China.

2. CIGB: Vaccines & Pharmaceutics Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba.

3. Yongzhou Zhong Gu Biotechnology Co., Ltd, Yongzhou, China.

4. Department of Laboratory Medicine, Dongguan Ninth People's Hospital, Dongguan, China.

5. BCF: BioCubafarma, Representative Office in China, Beijing, China.

6. Guangdong Eighth People's Hospital, Dongguan, China.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Molecular Medicine,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/vim.2022.0186

Reference27 articles.

1. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines

2. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

3. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity

4. Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of serological biomarkers of SARS-CoV-2 infection in convalescent samples from severe, moderate and mild COVID-19 cases. Front Immunol 2021;12 748291.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obtaining HBV core protein VLPs carrying SARS-CoV-2 nucleocapsid conserved fragments as vaccine candidates;2024-08-12

2. A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response;Vaccines;2024-05-28

3. The antiviral potential of the antiandrogen enzalutamide and the viral‐androgen signaling interplay in seasonal coronaviruses;Journal of Medical Virology;2024-03

4. The antiviral potential of the antiandrogen enzalutamide and the viral-androgen interplay in seasonal coronaviruses;2023-11-27

5. Cloning, expression, purification and characterization of the recombinant nucleocapsid protein from SARS-CoV-2 and its combination with a CpG ODN-39M;Bionatura;2023-09-15